ArticleAnnals of medicine and surgery (2012)2026
2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI in primary staging of epithelial ovarian cancer - an early interim analysis of a prospective clinical trial.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05855941 (Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In epithelial ovarian cancer (EOC), 2-fluorine-18-fluoro-deoxy-glucose (2-[18F]-FDG)-positron emission tomography (PET) with computed tomography (CT) outperforms CT and magnetic resonance imaging (MRI) in metastasis detection. The aim of this early interim study was to assess feasibility of the study workflow to evaluate accuracy of 2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI compared to stand-alone modalities in primary EOC staging. Methods: The first seven consecutive EOC participants in the prospective PRODIGYN study (NCT05855941) were included. All underwent 2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI at baseline and 6/7 at 3-month evaluation. Molecular imaging-based stage according to International Federation of Gynaecology and Obstetrics (miFIGO) with 2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI was compared to conventional radiological FIGO stage (crFIGO) with CT and MRI, using histopathological FIGO (pFIGO) as reference. At 3 months, therapy response assessment was performed with RECIST 1.1 and PERCIST. Results: At baseline, lymph node metastases were found in 3/7 with both modalities, and distant metastases in 2/7 with 2[18F]-FDG-PET/CT and 1/7 with PET/MRI. miFIGO was higher than crFIGO in 2/7, lower in 2/7, and the same in 3/7. At the 3-month therapy response assessment, RECIST 1.1 showed complete response in all, and PERCIST in 5/6, with partial response in 1/6. Conclusion: The PRODIGYN study workflow appears feasible for accuracy assessment of 2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI compared to stand-alone modalities in primary EOC staging. Early data indicate a possible added value of 2[18F]-FDG-PET/CT and 2[18F]-PET/MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.